ADAM17 and neoplasm: Future studies should focus on confirming tumor-derived exosomal ADAM17 as a plasma-based biomarker for the non-invasive screening of patients with CRC, as well as on the assessment of targeted ADAM17-based therapeutics against CRC liver metastasis.